510 related articles for article (PubMed ID: 32145134)
21. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
[TBL] [Abstract][Full Text] [Related]
22. Pathological considerations of CEUS LI-RADS: correlation with fibrosis stage and tumour histological grade.
Cheng MQ; Hu HT; Huang H; Pan JM; Xian MF; Huang Y; Kuang M; Xie XY; Li W; Wang W; Lu MD
Eur Radiol; 2021 Aug; 31(8):5680-5688. PubMed ID: 33502556
[TBL] [Abstract][Full Text] [Related]
23. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
Lee S; Kim SS; Chang DR; Kim H; Kim MJ
Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) v2017 in predicting malignant liver lesions in pediatric patients: a preliminary study.
Ludwig DR; Romberg EK; Fraum TJ; Rohe E; Fowler KJ; Khanna G
Pediatr Radiol; 2019 May; 49(6):746-758. PubMed ID: 31069473
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
[TBL] [Abstract][Full Text] [Related]
26. LI-RADS Major Features on MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Shin J; Lee S; Yoon JK; Chung YE; Choi JY; Park MS
J Magn Reson Imaging; 2021 Aug; 54(2):518-525. PubMed ID: 33638582
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
Kim YY; An C; Kim S; Kim MJ
Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI.
Ko A; Park HJ; Lee ES; Park SB; Kim YK; Choi SY; Ahn S
Clin Radiol; 2020 Apr; 75(4):319.e1-319.e9. PubMed ID: 31858990
[TBL] [Abstract][Full Text] [Related]
29. MRI-diagnosis of category LR-M observations in the Liver Imaging Reporting and Data System v2018: a systematic review and meta-analysis.
Shin J; Lee S; Hwang JA; Lee JE; Chung YE; Choi JY; Park MS
Eur Radiol; 2022 May; 32(5):3319-3326. PubMed ID: 35031839
[TBL] [Abstract][Full Text] [Related]
30. Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection.
Li L; Zheng W; Wang J; Han J; Guo Z; Hu Y; Li X; Zhou J
AJR Am J Roentgenol; 2022 Sep; 219(3):434-443. PubMed ID: 35441534
[No Abstract] [Full Text] [Related]
31. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
[No Abstract] [Full Text] [Related]
32. What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria?
Ghadimi M; Birnbaum J; Kamel IR; Sirlin CB; Chernyak V
Eur Radiol; 2022 May; 32(5):3327-3333. PubMed ID: 34807269
[TBL] [Abstract][Full Text] [Related]
33. MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients.
Huang Z; Zhou P; Li S; Li K
Ultrasound Med Biol; 2021 May; 47(5):1244-1252. PubMed ID: 33610338
[TBL] [Abstract][Full Text] [Related]
34. Identification of the origin of tumor in vein: comparison between CEUS LI-RADS v2017 and v2016 for patients at high risk.
Tong WJ; Cheng MQ; Lin MX; Hu HT; Pan JM; Huang H; Wang Y; Xie XY; Lu MD; Kuang M; Huang Y; Wang W
BMC Med Imaging; 2022 Oct; 22(1):186. PubMed ID: 36309665
[TBL] [Abstract][Full Text] [Related]
35. CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis.
van der Pol CB; McInnes MDF; Salameh JP; Levis B; Chernyak V; Sirlin CB; Bashir MR; Allen BC; Burke LMB; Choi JY; Choi SH; Forner A; Fraum TJ; Giamperoli A; Jiang H; Joo I; Kang Z; Kierans AS; Kang HJ; Khatri G; Kim JH; Kim MJ; Kim SY; Kim YY; Kwon H; Lee JM; Lewis SC; McGinty KA; Mulazzani L; Park MS; Piscaglia F; Podgórska J; Reiner CS; Ronot M; Rosiak G; Song B; Song JS; Tang A; Terzi E; Wang J; Wang W; Wilson SR; Yokoo T
Radiology; 2022 Feb; 302(2):326-335. PubMed ID: 34783596
[TBL] [Abstract][Full Text] [Related]
36. Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M.
Heo S; Kang HJ; Choi SH; Kim S; Yoo Y; Choi WM; Kim SY; Lee SS
Eur Radiol; 2024 May; 34(5):2974-2985. PubMed ID: 37848775
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS.
Hu YX; Shen JX; Han J; Mao SY; Mao RS; Li Q; Li F; Guo ZX; Zhou JH
Front Oncol; 2021; 11():641195. PubMed ID: 33912456
[TBL] [Abstract][Full Text] [Related]
38. Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-Analysis.
Zhou Y; Qin Z; Ding J; Zhao L; Chen Y; Wang F; Jing X
Front Oncol; 2022; 12():873913. PubMed ID: 35425706
[TBL] [Abstract][Full Text] [Related]
39. Liver Imaging Reporting and Data System Version 2018: Impact on Categorization and Hepatocellular Carcinoma Staging.
Chernyak V; Flusberg M; Berman J; Fruitman KC; Kobi M; Fowler KJ; Sirlin CB
Liver Transpl; 2019 Oct; 25(10):1488-1502. PubMed ID: 31344753
[TBL] [Abstract][Full Text] [Related]
40. Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
Lee S; Kim MJ; Kim SS; Shin H; Kim DY; Choi JY; Park MS; Mitchell DG
Hepatol Int; 2020 Jan; 14(1):70-79. PubMed ID: 31802388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]